These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Direct-to-consumer marketing of stem cell interventions by Canadian businesses. Turner L Regen Med; 2018 Sep; 13(6):643-658. PubMed ID: 30255734 [TBL] [Abstract][Full Text] [Related]
4. Vulnerabilities and the Use of Autologous Stem Cells for Medical Conditions in Australia. Hendl T Perspect Biol Med; 2018; 61(1):76-89. PubMed ID: 29805149 [TBL] [Abstract][Full Text] [Related]
5. Stem cell clinics online: the direct-to-consumer portrayal of stem cell medicine. Lau D; Ogbogu U; Taylor B; Stafinski T; Menon D; Caulfield T Cell Stem Cell; 2008 Dec; 3(6):591-4. PubMed ID: 19041775 [TBL] [Abstract][Full Text] [Related]
6. Unproven stem cell-based interventions and achieving a compromise policy among the multiple stakeholders. Matthews KR; Iltis AS BMC Med Ethics; 2015 Nov; 16(1):75. PubMed ID: 26537611 [TBL] [Abstract][Full Text] [Related]
7. Stem cell research and therapies in Argentina: the legal and regulatory approach. de Arzuaga FC Stem Cells Dev; 2013 Dec; 22 Suppl 1():40-3. PubMed ID: 24304074 [TBL] [Abstract][Full Text] [Related]
8. The deadly business of an unregulated global stem cell industry. Lysaght T; Lipworth W; Hendl T; Kerridge I; Lee TL; Munsie M; Waldby C; Stewart C J Med Ethics; 2017 Nov; 43(11):744-746. PubMed ID: 28356490 [TBL] [Abstract][Full Text] [Related]
9. Reflection on the enactment and impact of safety laws for regenerative medicine in Japan. Takashima K; Morrison M; Minari J Stem Cell Reports; 2021 Jun; 16(6):1425-1434. PubMed ID: 34019814 [TBL] [Abstract][Full Text] [Related]
10. Editors' Introduction to the Special Section on Ethics, Policy, and Autologous Cellular Therapies. Lysaght T; Sugarman J Perspect Biol Med; 2018; 61(1):1-6. PubMed ID: 29805144 [No Abstract] [Full Text] [Related]
11. Stem cells and the heart: ethics, organization and funding. Martin JF Nat Clin Pract Cardiovasc Med; 2006 Mar; 3 Suppl 1():S136-7. PubMed ID: 16501621 [TBL] [Abstract][Full Text] [Related]
12. Centre for Commercialization of Regenerative Medicine: moving forward with regenerative medicine commercialization in Canada. Johnson S Stem Cells Dev; 2013 Dec; 22 Suppl 1():85-8. PubMed ID: 24304082 [No Abstract] [Full Text] [Related]
13. [Ethics of stem cell therapy for heart failure]. Díaz-Navarro R; Pérez-Terzic C Rev Med Chil; 2019 Jun; 147(6):787-789. PubMed ID: 31859832 [TBL] [Abstract][Full Text] [Related]
14. Compassionate use of experimental therapies: who should decide? Zettler PJ EMBO Mol Med; 2015 Oct; 7(10):1248-50. PubMed ID: 26202382 [TBL] [Abstract][Full Text] [Related]
15. Broadening the scope of debates around stem cell research. Lysaght T; Campbell AV Bioethics; 2013 Jun; 27(5):251-6. PubMed ID: 22500617 [TBL] [Abstract][Full Text] [Related]
16. Allogeneic and autologous mode of stem cell transplantation in regenerative medicine: which way to go? Mamidi MK; Dutta S; Bhonde R; Das AK; Pal R Med Hypotheses; 2014 Dec; 83(6):787-91. PubMed ID: 25456787 [TBL] [Abstract][Full Text] [Related]
17. Health consumers and stem cell therapy innovation: markets, models and regulation. Salter B; Zhou Y; Datta S Regen Med; 2014 May; 9(3):353-66. PubMed ID: 24935045 [TBL] [Abstract][Full Text] [Related]
18. Stem cells: taking a stand against pseudoscience. Cattaneo E; Corbellini G Nature; 2014 Jun; 510(7505):333-5. PubMed ID: 24955466 [No Abstract] [Full Text] [Related]
19. Of stem cells and ethics. Nat Cell Biol; 2017 Nov; 19(12):1381. PubMed ID: 29184178 [No Abstract] [Full Text] [Related]
20. Assessing commercial opportunities for autologous and allogeneic cell-based products. Smith DM Regen Med; 2012 Sep; 7(5):721-32. PubMed ID: 22954441 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]